Correlation of anti-tumour drug resistance with epigenetic regulation-Reference-Cited by-同舟云学术

Correlation of anti-tumour drug resistance with epigenetic regulation

Published:2020-12-03 Issue:4 Volume:124 Page:681-682
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Hayashi Takuma^ORCID,Konishi Ikuo

Abstract

SummaryDuring treatment, the development of drug-resistant tumours remains an important challenge in cancer treatment. Epigenetic changes have been reported as one of the mechanisms for anti-tumour drug resistance. In clinical practice, a combination of epigenetic-related drugs can be considered as a future selection of cancer therapeutic drugs.

Funder

START-program Japan Science and Technology Agency (JST) for TH

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-020-01183-y.pdf

Reference7 articles.

1. Huang, T., Song, C., Zheng, L., Xia, L., Li, Y. & Zhou, Y. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. Mol. Cancer 18, 62 (2019).

2. Manasanch, E. E. & Orlowski, R. Z. Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 14, 417–433 (2017).

3. Barrio, S., Stühmer, T., Da-Viá, M., Barrio-Garcia, C., Lehners, N., Besse, A. et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 33, 447–456 (2019).